Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Mouse Transforming Growth Factor β1 (mTGF-β1) #5231

Request pricing for multi-milligram amounts.

Source

Recombinant mouse TGF-β1 (hTGF-β1) Ala279-Ser390 (Accession #NP_035707) was expressed in human 293 cells at Cell Signaling Technology.

Molecular Characterization

Recombinant mTGF-β1 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,810. DTT-reduced protein migrates as a 13 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 25 kDa protein. The expected amino-terminal ALDTN of recombinant mTGF-β1 was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mTGF-β1. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant mTGF-β1 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 40-200 pg/ml.

Coomassie Gel

Coomassie Gel

The purity of recombinant mTGF-β1 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mTGF-β1 and staining overnight with Coomassie Blue.

Bioactivity

Bioactivity

The inhibition of IL-4 induced proliferation in HT-2 cells treated with increasing concentrations of mTGF-β1 was assessed. After 48 hour treatment with mTGF-β1, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.

Western Blotting

Western Blotting

Western blot analysis of extracts from HT-2 cells, untreated or treated with the mTGF-β1 for 20 minutes, using Phospho-Smad2 (Ser465/467) (138D4) Rabbit mAb #3108 (upper) and Smad2 (D43B4) XP® Rabbit mAb #5339 (lower).


Endotoxin

Less than 0.01 ng endotoxin/1 μg mTGF-β1.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg mTGF-β1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

Background

TGF-β1 activities include proliferation, angiogenesis, and promotion or inhibition of many immune events (1-3). TGF-β1 is produced by a number of cell types including regulatory T cells, fibroblasts, epithelial cells, and endothelial cells (3). TGF-β1 binds to TβRII homodimer, which then complexes with TβRI homodimer (1,4). The oligomeric receptor complex phosphorylates subsets of the Smad proteins that then act to induce and repress a number of target genes (1,3,4). TGF-β1 binding can also activate the Erk2, p38, and JNK pathways via TAK1 (4). TGF-β1 appears to promote late stage progression and metastasis in some cancers (1,2).

  1. Siegel, P.M. and Massagué, J. (2003) Nat Rev Cancer 3, 807-21.
  2. Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20.
  3. Tian, M. and Schiemann, W.P. (2009) Future Oncol 5, 259-71.
  4. Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products